FORMULATION AND EVALUATION OF FLOATING PULSATILE DRUG DELIVERY OF ENALAPRIL

Abstract

Enalapril is almost like a angiotensin-converting enzyme (ACE) inhibitor that is used to 
treat hypertension, heart failure, and heart attacks. It belongs to BCS class III, with a half
life of 12 hours and a bioavailability of 25%. The goal of this study was to create a floating
pulsatile medication delivery device that was presscoated. The superdisintegrants 
crosprovidone and croscarmellose sodium were used to make the core tablet. Carrageenan, 
xanthan gum, HPMC K4M, and HPMC E15LV were all found in a press-coated tablet 
(barrier layer). HPMC K100M, sodium bicarbonate, and citric acid were used to maximise 
the buoyant layer. Physical properties, floating lag time, swelling index, FTIR, DSC, and in 
vitro and in vivo behaviour were all assessed. The 5% superdisintgrant yielded positive 
results. No chemical interactions between the medication and the excipients were 
anticipated by the FTIR and DSC studies. Drug retention was demonstrated in the xanthan 
gum-containing formulation, although it did not float. The swelling index of the HPMC 
K15M pill was high. The in vitro release profiles of Enalapril from PRT prepared with 
HPMC E15LV as the retarding polymer are characterised by a predetermined lag time 
(4.10.2 h for K6+F4), the length of which is dependent on the type and amount of the 
polymeric layer applied to the cores, as well as the type of superdisintegrant in the core 
tablet. The presented technology provides a simple and unique method for medication pulse 
release. Based on the findings, we can infer that the PRT we developed could accomplish a 
quick release with minimal variability after a lag period of 40.2 hours.